Damona Pharmaceuticals Analysis: $6M Raised
What is Damona Pharmaceuticals?
Damona Pharmaceuticals develops microcircuit precision medicines aimed at restoring cognitive functions in patients with brain disorders. Their lead program is a positive allosteric modulator targeting the α5-GABA-A receptor, which is designed to reverse cognitive deficits. The company focuses on therapies that restore connections between brain cells to improve the quality of life for patients suffering from cognitive impairments.
Location
250 College Street, Suite 131, Toronto, Ontario M5T 1R8, Canada
Employees
1-10
Founded
2019
Funding Status
Seed
Product Features & Capabilities
- DPX-101, a positive allosteric modulator targeting α5-GABA-A receptor
Use Cases
Treat cognitive deficits in Alzheimer's disease; Address cognitive impairments across various brain disorders; Restore connections between brain cells; Improve life quality for patients with cognitive deficits; Support clinical trials for neurological therapies
Other Considerations
Published preclinical proof of concept data for DPX-101; IND application clearance for Phase 1 trial of DPX-101; Focus on cognitive deficits in Alzheimer's and other brain disorders
See something that needs updating? Suggest edits to this profile.